Futura Medical plc (AIM: FUM), a pharmaceutical company developing a portfolio of … Continue reading “Highly positive FM71 Phase 3 Study Results with all primary and secondary endpoints achieved, MED3000 remains on track to obtain US FDA marketing authorisation”
Brighton, United Kingdom – 22 September 2022 – Destiny Pharma plc (AIM:DEST), a clinical … Continue reading “Destiny Pharma plc – Notice of R&D Update Meeting”
Denmark’s first fully functional generally applicable quantum computer will be available in … Continue reading “Novo Nordisk Foundation: Major investment for developing Denmark’s first fully functional quantum computer”
BioInnovation Institute (BII) announces that it has entered a collaboration with Imperial … Continue reading “World-class translational project enters the Bio Studio program as part of collaboration with Imperial College London”
BERLIN, 15 September 2022 – Ariceum Therapeutics (Ariceum), a private biotech company developing … Continue reading “Ariceum Therapeutics Q4 2022 Investor and Scientific Conference”
AMSTERDAM, NETHERLANDS – 15th September 2022 — Synaffix B.V., a biotechnology company focused … Continue reading “Synaffix Wins ‘Best ADC Platform Technology’ Award Again at World ADC Awards Ceremony 2022”
Futura Medical plc (AIM: FUM), a pharmaceutical company developing a portfolio of innovative … Continue reading “Futura Medical Interim Results for the Six Months ended 30 June 2022”
STORM recognised as an innovative early-stage biotechnology company pioneering novel drug targets … Continue reading “Fierce Biotech names STORM Therapeutics as one of its “Fierce 15” Biotech Companies of 2022”
alfapump® – strong interim data / on track to report primary endpoint … Continue reading “Sequana Medical announces H1 2022 results and provides business update”
The Pedro J. Romero Award recognizes individuals who have made outstanding contributions … Continue reading “Professor Melief to receive 2022 SITC Pedro J. Romero Award”
7 September 2022, Cambridge, UK: STORM Therapeutics Ltd. (STORM), the biotechnology company discovering … Continue reading “STORM Therapeutics Appoints Dr. Jerry McMahon as Chief Executive Officer”
BioInnovation Institute (BII), an international commercial non-profit foundation incubating and accelerating world-class … Continue reading “BII announces new cohort of companies entering the Venture Lab program”
Dublin, Ireland, 31 August 2022: SynOx Therapeutics Limited (“SynOx” or the “Company”), the … Continue reading “Emactuzumab designated as an Orphan Medicinal Product in Europe”
BANGALORE, INDIA – FOSTER CITY, USA – SINGAPORE – 30 August 2022 – … Continue reading “Novo Holdings leads US$50M investment in South Asia–based MedGenome”
Bactolife today announced that the Bill & Melinda Gates Foundation has committed, … Continue reading “Novo Holdings portfolio company Bactolife receives new funding to advance lifesaving protein technology”
Ghent, Belgium – 25 August 2022 – Sequana Medical NV (Euronext Brussels: SEQUA) (the “Company” or … Continue reading “Alexandra Clyde appointed to Sequana Medical Board of Directors”
LONDON and RALEIGH, N.C., Aug. 24, 2022 (GLOBE NEWSWIRE) — Verona Pharma … Continue reading “Verona Pharma strengthens commercialization leadership team”
BII announces that four companies have joined its new Venture House program. … Continue reading “BII announces new Venture House program and initial intake of four innovative companies”
BII today announces its investment into three international start-up companies from the … Continue reading “BII supports three international start-ups developing pioneering science in the therapeutics and health tech space”
For more information about Optimum Strategic Communications, please get in touch
We'd love to hear from you...
GET IN TOUCH
© Copyright 2022 Optimum Strategic Communications All rights reserved.
The Spice Building
8 Devonshire Square
London
EC2M 4PL
Tel: +44 (0)203 950 9144
Email: contact@optimumcomms.com
